Brought to you by 
Series D brings in $20mm for GlySens
13 Jan 2016
Executive Summary
Glucose monitoring firm GlySens Inc. raised $20mm in its Series D financing led by undisclosed Series C backers as well as new investors. Funds will help the company continue clinical trials of its fully implanted ICGM system as it prepares to file for the CE mark, hire additional staff, and finish building a new manufacturing facility.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D brings in $20mm for GlySens
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice